Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C1323099 (sympathomimetic)
 2,957 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

1. The effects of sustained moderate exercise in the sitting position on renal haemodynamics and glomerular filtration were measured in six normotensive patients with moderately impaired renal function and seven age-matched normal volunteers. 2. The changes in the effects of exercise on renal function induced by chronic cardioselective beta-adrenoceptor blockade by drugs with (epanolol) and without intrinsic sympathomimetic activity (atenolol) were examined. 3. Both beta-adrenoceptor blockers attenuated the heart rate increase with exercise, but only atenolol lowered blood pressure significantly. In resting volunteers on atenolol, associated with the fall in blood pressure there was a significant reduction in glomerular filtration rate. 4. Glomerular filtration fell significantly in all groups with exercise, and renal blood flow also fell in parallel. These changes were not influenced by drug treatment. 5. The exercise-induced rise in PRA was suppressed by atenolol but not by epanolol. 6. The renal function and haemodynamic responses to moderate exercise does not appear to be mediated by the systemic renin-angiotensin system or by beta 1-adrenoceptors.
 ...
PMID:The effects of selective beta-adrenoceptor antagonists and partial agonist activity on renal function during exercise in normal subjects and those with moderate renal impairment. 168 67

1-tert.-Butylamino-3-(2-cyclopentylphenoxy)-propan-2-ol (penbutolol, Hoe 893d) is a beta-adrenergic blocking agent about 4 times more active than propranolol in vivo and in vitro. In comparison to propranolol it is characterized by a longer lasting activity. The antihypertensive effect of penbutolol in spontaneously hypertonic rats is more than 5 times stronger than that of propranolol. Penbutolol reduces basal plasma renin activity in the same dose range as does propranolol but is about 3 times stronger with respect to isoproterenol-induced increase of PRA. Penbutolol is 5 times more potent than propranolol inhibiting isoproterenol-stimulated phosphorylase activity in the isolated heart. In reserpine pretreated rats, penbutolol has a moderate intrinsic sympathomimetic activity (ISA). Penbutolol shows less unspecific actions -- such as negative inotropy or calcium antagonism -- than propranolol. Characteristic parameters of lung function (compliance and resistance) are less affected by penbutolol than propranolol in spite of the fact that penbutolol has a stronger beta-adrenergic blocking effect.
 ...
PMID:[On the pharmacology of the beta-receptor blocker penbutolol (author's transl)]. 699 88